Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy (SPACE study)
Open Access
- 14 February 2021
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 12 (8), 1264-1268
- https://doi.org/10.1111/1759-7714.13880
Abstract
Afatinib is an ErbB family blocker approved for the treatment of epidermal growth factor receptor mutation‐positive nonsmall‐cell lung cancer. A pivotal trial demonstrated significant clinical benefits with manageable toxicity of afatinib as a second‐line treatment option in squamous cell carcinoma of the lung (SCC) which led to approval in >60 countries. However, these results were derived from a controlled study conducted in selected patients and are not necessarily representative of the real‐world use of this drug. In addition, data on afatinib use after immunotherapy in this clinical setting are lacking. The aim of this study is to evaluate the treatment outcomes and safety of afatinib as a second‐ or later‐line treatment for SCC and to identify potential predictive biomarkers. As a real‐world observational study, 130 eligible patients with advanced SCC, who progressed after platinum‐based chemo‐ and immunotherapy, will be enrolled. Treatment outcomes and safety data will be collected for both the retrospective and prospective cohorts, and molecular profiling using tissue and plasma will be performed for the prospective cohort. The primary endpoint is time to treatment failure, and the secondary endpoints are objective response rate, progression‐free survival, overall survival, and safety. Comparison of clinical outcomes with respect to the different programmed death‐ligand 1 expression and molecular characteristics will also be carried out. This study will provide additional evidence on the usefulness of afatinib as a subsequent treatment, as well as feasible molecular biomarkers to predict its efficacy in this clinical setting.Keywords
This publication has 27 references indexed in Scilit:
- Current Status of Immunotherapy for Lung Cancer and Future PerspectivesTuberculosis and Respiratory Diseases, 2020
- Trends and Updated Statistics of Lung Cancer in KoreaTuberculosis and Respiratory Diseases, 2019
- Chemotherapy for Lung Cancer in the Era of Personalized MedicineTuberculosis and Respiratory Diseases, 2019
- Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer RegistryTuberculosis and Respiratory Diseases, 2019
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2018
- Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized MedicineFrontiers in Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010PLOS ONE, 2015
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012